title: Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer.
abstract: Tumor necrosis factor receptor 2 (TNFR2) is expressed both by some cancer cells and by tumor-infiltrating immunosuppressive CD4+FoxP3+regulatory T cells (Tregs). TNFR2 stimulates the activation and proliferation of Tregs, a major checkpoint of antitumor immune responses, and promotes cancer cell survival and tumor growth. In this issue of Science Signaling, Torrey et al found that dominant antagonistic antibodies against human TNFR2 may be a potential therapy for ovarian cancer patients by simultaneously suppressing Tregactivity and inducing the death of the cancer cells.
authors.affiliation: State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao S.A.R. 999078, China. xchen@umac.mo oppenhej@mail.nih.gov.|Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.
authors.forename: Xin
authors.initials: X
authors.lastname: Chen
authors.affiliation: Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA. xchen@umac.mo oppenhej@mail.nih.gov.
authors.forename: Joost J
authors.initials: JJ
authors.lastname: Oppenheim
mesh_terms: D049109:Cell Proliferation; D005260:Female; D006801:Humans; D015513:Oncogene Proteins; D010051:Ovarian Neoplasms; D047889:Receptors, Tumor Necrosis Factor, Type II / Q000037:antagonists & inhibitors*; D050378:T-Lymphocytes, Regulatory / Q000166:cytology
chemical_list: D015513:Oncogene Proteins; D047889:Receptors, Tumor Necrosis Factor, Type II